Skip to content
Menu

Liquidia Corporation LQDA

Full chart Compare
Set alert

Price alert · LQDA

All alert types
56.63 USD +0.23 (+0.41%)

Regular-session close

56.32 -0.31 -0.55%

Pre-market · Nov 20, 6:41 AM ET

54.39 Day range 57.32
22.31 52-week range 93.61
YTD
+64.19%
1 year
+91.06%

5D -1.63 (-2.80%)

5658FriMonTueWedThu56.63
Market cap
5.10B
Revenue (ttm)
621.87M
Profit margin
-15.15%
EPS (ttm)
-1.05
Shares out
90.11M
Forward P/E
15.73
YTD return
+64.19%
1-year return
+91.06%
50-day average
48.24
200-day average
54.89
Volume
1.34M
Avg volume
3.52M
Open
56.33
Previous close
56.40
Day's range
54.39 – 57.32
52-week range
22.31 – 93.61
Beta
0.41
Analysts
Buy
Price target
66.13 (+16.8%)
Earnings date
Mar 4, 2027

Key statistics

Enterprise value
4.85B
Price / sales
8.21
Revenue growth
314.60%
Free cash flow
535.60M
Total cash
396.09M
Total debt
168.76M
Short % of float
24.07%

Fundamental scorecard

10 of 25 checks passed on LQDA’s reported financials

ValueGrowthProfitabilityHealthDividend

10of 25 checks passed

  • Value 2 of 5
  • Growth 3 of 5
  • Profitability 1 of 5
  • Financial health 4 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
LQDA Revenue — quarterly 225.30M
LQDA Net income — quarterly -236.33M
LQDA EPS — quarterly -2.64

Earnings

LQDA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 4, 2027Dec 30, 20260.97———
Nov 10, 2026Sep 30, 20260.96-2.64-3.60-375.00%
Aug 12, 2026Jun 30, 20260.700.74+0.04+5.71%
May 11, 2026Mar 31, 20260.340.52+0.18+52.94%
Mar 5, 2026Dec 31, 20250.080.15+0.07+87.50%
Nov 3, 2025Sep 30, 2025-0.45-0.04+0.41+91.11%

Upgrades / downgrades

LQDA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 11, 2026Wells FargomainEqual-WeightEqual-Weight
Nov 11, 2026NeedhammainBuyBuy
Nov 10, 2026JefferiesmainBuyBuy
Nov 10, 2026BTIGmainBuyBuy
Oct 15, 2026HC Wainwright & Co.mainBuyBuy
Oct 14, 2026LifeSci CapitalupMarket PerformOutperform

About Liquidia Corporation

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for rare cardiopulmonary diseases in the United States. The company's lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also provides Remodulin, a treprostinil injection administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil which is in phase III clinical trial for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). In addition, the company offers PRINT technology which allows to engineer and manufacture uniform drug particles with precise control over the size, three-dimensional geometric shape, and chemical composition of the particles. It has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD; Vectura; The University of North Carolina at Chapel Hill; GlaxoSmithKline; Alcon Inc; and promotion Agreement with Sandoz. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
United States
Website
liquidia.com

News

Your note

Sign in to keep a note on LQDA — it syncs with the Stock Master app.

Insider holders

LQDA insider holders
InsiderRelationLatest transactionDateShares held
ADAIR JASONOfficerSaleOct 25, 2026177,269
BLOCH STEPHEN M.DirectorSaleJul 22, 20260
BOYLE DANAOfficerSaleOct 25, 2026164,028
CALIGAN PARTNERS L,P.Beneficial Owner of more than 10% of a Class of SecuritySaleMay 18, 20260
JEFFS ROGER AChief Executive OfficerSaleOct 11, 20262,214,110
JOHNSON DAVID EDWARDDirector and Beneficial Owner of more than 10% of a Class of SecurityStock Award(Grant)Jun 15, 20260

Institution ownership

LQDA institution ownership
Holder% heldSharesValueReported
Blackrock Inc.12.50%11,261,934637.76MSep 29, 2026
Farallon Capital Management LLC9.88%8,906,038504.35MSep 29, 2026
Caligan Partners, LP9.01%8,118,892459.77MSep 29, 2026
Findell Capital Management LLC4.03%3,635,112205.86MSep 29, 2026
Vanguard Capital Management LLC3.59%3,237,894183.36MSep 29, 2026
State Street Corporation3.57%3,215,400182.09MSep 29, 2026

Fund ownership

LQDA fund ownership
Holder% heldSharesValueReported
iShares Trust-iShares Core S&P Small-Cap ETF4.91%4,424,930250.58MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.51%2,259,289127.94MJun 29, 2026
iShares Trust-iShares Russell 2000 ETF2.03%1,826,128103.41MSep 29, 2026
Invesco Exchange-Traded Fund Trust-Invesco S&P SmallCap Momentum ETF0.93%841,08847.63MSep 29, 2026
Capitol Series Trust-FullerThaler Behavioral Small-Cap Growth Fund0.90%812,80046.03MJun 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.89%805,88045.64MJun 29, 2026